Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-17
2011-05-17
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S567000
Reexamination Certificate
active
07943632
ABSTRACT:
Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual at least 1000 mg or more of L-dopa (levodopa) per day. The use of potent dopaminergic agents to stimulate emergence from an altered consciousness state, such as a coma, is disclosed.
REFERENCES:
patent: 3961060 (1976-06-01), Fuxe
patent: 5770606 (1998-06-01), El-Rashidy et al.
patent: 5858024 (1999-01-01), De Lacharriere et al.
patent: 5957873 (1999-09-01), Allen
patent: 6306437 (2001-10-01), El-Rashidy et al.
patent: 6310085 (2001-10-01), Willis
patent: 6436950 (2002-08-01), Achari et al.
patent: 6463328 (2002-10-01), John
patent: 6492396 (2002-12-01), Bacon et al.
International Preliminary Report on Patentability (IPRP) for international application No. PCT/US04/08120 (Oct. 6, 2005).
Written Opinion of the International Searching Authority for international application No. PCT/US04/08120 (Oct. 25, 2004).
International Search Report for international application No. PCT/US04/08120 (Oct. 25, 2004).
Supplementary European Search Report for European patent application No. 04757552 (Nov. 18, 2008).
Haig et al.,Arch. Phys. Med. Rehab. II, 71: 1081-1083 (1990) (from Suppl. European Search Report).
Mitchell et al.,Brain Injury, 4(3): 273-279 (1990) (from Suppl. European Search Report).
Tang et al.,European Journal of Neuroscience, 9: 1720-1727 (1997) (from Suppl. European Search Report).
Velluz, J.,Revue Du Corps De Sante Militaire, 8(2): 275-282 (1952) (abstract) (from Suppl. European Search Report).
Ashwal,Brain&Develp., 25: 535-545 (2003).
Colosimo et al.,Clin. Neuropharmocol., 17(3): 243-259 (1994).
Giacino et al.,Arch. Phys. Med. Rehahbil., 72: 897-901 (1991).
Giacino et al.,JFK Coma Recovery Scale and Coma Intervention Program Treatment Procedures, (Center for Head Injuries, JFK Johnson Rehabilitation Institute, Edison, New Jersey), pp. 1-25 (1992).
Giacino et al.,Neurology, 58: 349-353 (2002).
Haig et al.,Arch. Phys. Med. Rehabil., 71: 1081-1083 (1990).
Jennet et al.,Lancet, 1: 480-484 (1975).
Lees et al.,Fund. Clin. Pharmacol., 7: 121-128 (1993).
Meythaler et al.,J. Head Trauma Rehabil., 17(4): 300-313 (2002).
Missale et al.,Physiol. Rev., 78(1): 189-216 (1998).
Nicolle et al.,Fund. Clin. Pharmacol., 7: 245-252 (1993).
O'Dell et al.,Neurorehabil., 6: 45-55 (1996).
Passler et al.,Arch. Phys. Med. Rehabil., 82: 311-315 (2001).
Pilon et al.,Brain Injury, 10(6): 421-437 (1996).
Rappaport et al.,Arch. Phys. Med. Rehabil., 63: 118-123 (1982).
Rappaport et al.,Arch. Phys. Med. Rehabil., 73: 628-634 (1992).
Spiridonov V.K. et al.,Activity of dopaminergic terminals of rat forebrain nuclei during electroconvulsive amnesia and reproduction of conditioned reaction of “Passive” avoidance restored with apomorphine, 31(2): 409-411 (1981)(Russian document and English translation enclosed).
Talbot et al.,Brain Injury, 8(8): 689-699 (1994).
Whyte et al.,J. Head Trauma Rehabil., 17(4): 284-299 (2002).
Wilson et al.,J. Neurotrauma, 15(8): 573-585 (1998).
Wolf et al.,Brain Injury, 9(5): 487-493 (1995).
Zafonte et al.,J. Head Trauma Rehabil., 15(5): 1179-1182 (2000).
Ashwal,Brain&Development, 25: 535-545 (2003).
Colosimo et al.,Clinical Neuropharmacology, 17(3): 243-259 (1994).
Giacino et al., JFK Coma Recovery Scale and Coma Intervention Program Treatment Procedures, (Center for Head Injuries, JFK Johnson Rehabilitation Institute, Edison, New Jersey) p. 1-25 (1992).
Giacino et al.,American Academy of Neurolgy, 58: 349-353 (2002).
Giacino et al.,Arch. Phys. Med. Rehabil., 72: 897-901 (1991).
Haig et al.,Arch. Phys. Med. Rehabil., 71: 1081-1083 (1990).
Jennet et al.,The Lancet, 1: 480-484 (1975).
Kaplan et al.,Clinical Neurology and Neurosurgery, 105: 153-155 (2003).
Lees AJ,Fundam. Clin. Pharmacol., 7: 121-128 (1993).
Meythaler et al.,J. Head Trauma Rehabil., 17(4): 300-313 (2002).
Missale et al.,Physiological Reviews, 78(1): 189-225 (1998).
Nicolle et al.,Fundam. Clin. Pharmacol., 7: 245-252 (1993).
Passler et al.,Arch. Phys. Med. Rehab., 82: 311-315 (2001).
Pilon et al.,Brain Injury, 10(6): 421-437 (1996).
Rappaport et al.,Arch. Phys. Med. Rehabil., 63: 118-123 (1982).
Rappaport et al.,Arch. Phys. Med. Rehabil., 73: 628-634 (1992).
Spiridonov et al.,Zh. vysshei nerv. deiat. Pavlova, 31(2): 409-411 (1981) (in Russian with English translation attached).
Talbot et al.,Brain Injury, 8(8): 689-699 (1994).
van Woerkom et al.,Eur. Neurol., 21: 227-234 (1982).
Whyte et al.,J. Head Trauma Rehabil., 17(4): 284-299 (2002).
Wilson et al.,Journal of Neurotrauma, 15(8): 573-585 (1998).
Wolf et al.,Brain Injury, 9(5): 487-493 (1995).
Zafonte et al.,J. Head Trauma Rehabil., 15(5): 1179-1182 (2000).
The Multi-Society Task Force on Persistent Vegetative State (PVS),N. Engl. J. Med., 330(21): 1499-1508 (1994).
The Multi-Society Task Force on PVS,N. Engl. J. Med., 330(22): 1572-1579 (1994).
Farber Neal M.
Fridman Esteban A.
Gamzu Elkan R.
Katzman Daniel E.
Merello Marcelo
NeuroHealing Pharmaceuticals, Inc.
O'Brien David G.
Weddington Kevin
Yankwich Leon R.
Yankwich & Associates P.C.
LandOfFree
High potency dopaminergic treatment of neurological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High potency dopaminergic treatment of neurological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High potency dopaminergic treatment of neurological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690553